‘Formulating better medicines for children’ – The leap forward  by Salunke, Smita & Tuleu, Catherine
International Journal of Pharmaceutics 469 (2014) 225–227‘Formulating better medicines for children’ – The leap forward
Contents lists available at ScienceDirect
International Journal of Pharmaceutics
journal homepage: www.elsev ier .com/locate / i jpharmTaking the leap forward towards the awareness and under-
standings of the paediatric-speciﬁc issues in the development of
paediatric formulations, the European Paediatric Formulation
Initiative (EuPFI) convoked its 5th annual conference in association
with the International Association of Pharmaceutical Technology
(APV). The conference was held on 18th and 19th September 2013
at the Hotel Porta Fira in Barcelona, Spain. The participation of 162
delegates from industry, academia, regulatory and other organiza-
tions from 27 countries with diverse backgrounds and involvement
in both formulation development and regulatory submissions,
provided a productive setting for the exchange of information and
views.
Following feedback received from the previous conference, a
new format, including pre-conference workshops and innovative
showcase, was introduced. The programme for this 2-day
conference was participant driven and touched upon a range of
topics for product development with the patient’s point of view. In
addition, the conference provided the opportunity for practitioners
from different disciplines to discuss aspects and issues of
formulating paediatric medicines including understanding the
research needs for children’s medicines, developing new medi-
cines for children or adapting existing medicines so that they could
be used safely and effectively in children and improving ways to
encourage children to take their medicines.
Two pre-conference workshops led by specialists in each topic
area, gave an opportunity for the participants to maximize their
learningexperience. The ﬁrst workshop chaired by Prof. Adolf Valls-i-
Soler (University of the Basque Country) provided an in-depth review
and scientiﬁc discussion on how developmental changes may
inﬂuence the pharmacokinetics and pharmacodynamics of drugs,
how pharmacokinetics could be predicted in neonates, infants and
children and how it can be linked to pharmacodynamics. The second
workshop by Dr. Dirk Mentzer (PDCO, EMA) was an opportunity to
learn how the regulatory professionals interpret the paediatric
regulation and implement it inpractice.1 Inparticular, how setting up
a paediatric investigation plan links up with the various phases of
drug development (designation, protocol assistance, and marketing
authorisation).
Long standing problems with potential health risks in children
have triggered an international response in the form of the European
Union (EU)-funded seventh framework programme FP7/2007–13
under grant agreement n 261060 GRiP (global research in
paediatrics) project. The keynote plenary lecture by Dr. Kalle Hoppu1
PDCO - Paediatric Expert Committee at the European Medicines Agency (EMA).
http://dx.doi.org/10.1016/j.ijpharm.2014.04.037
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The main characteristics of GRiP, infrastructure matrix, expected
impact and key areas of work were introduced. The work of GRiP has
been divided into nine work packages, each dealing with a
fundamental aspect of research and development of medicines for
children, the output from which will be the development of a
paediatric clinical pharmacology training programme and ﬁlling
important “gaps" in paediatric medicines research by the validation
and harmonization of research tools speciﬁc for paediatrics. The
additional information is available on GRiP website (http://www.
grip-network.org).
Development of age-appropriate formulations is an essential part
of paediatric drug development and adds additional biopharmaceu-
tical considerations to an already complex problem. Dr. Hannah
Batchelor (University of Birmingham) presented the limitations of
the biopharmaceutics classiﬁcation system (BCS) and its use in the
development of paediatric medicines. It was highlighted that more
research is needed in this area, including potential development of a
predictive dissolution testing method, which could correlate in vitro
data with in vivo product performance. In turn having patients as a
partner in the process towards innovative medicines would add
another helpful dimension in identifying the unmet therapeutic
needs considering risks and beneﬁts. Dr. Cor Oosterwijk (the
patients network for medical research and health EGAN) reiterated
this message in his presentation that the parent/patient organiza-
tions have an important role in these developments and interaction
between parents and children and the research ﬁeld will contribute
to innovation and quality of treatment and care. Actual European
developments in health care policyconcerning rare diseases are also
of relevance for the research infrastructure in paediatric medicine
and paediatric formulations.
While progress has been most notable in the United States (US)
and the European (EU) community, there is growing recognition of
the needfor bettermedicines for childrenworldwide. While there are
many similarities between US and EU regulatory guidelines, there
remain important and critical differences. European legislation
involves both the countries and EU speciﬁc guidelines. Within Japan
the off-license or unlabelled use of drugs in children is as common as
in the US and EU, however, there is no paediatric legislation, although
there are efforts to develop such legislation. Dr. Hide Nakamura
(National Research Institute for Child Health and Development)
provided the insight into the current paediatric research situation in
Japan. The various aspects related to paediatric formulation and
extemporaneous use of medicines in Japan was discussed from
different view points, from the view of a clinician, of the
pharmaceutical industry and from the government.
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the paediatric over the counter (OTC) segment. Dr. Paul Goggin
(Pﬁzer) provided a background to the innovations that are made in
over the counter market and outlined the time and costs involved
in these activities.
Conﬁrmation of the acceptability is an important aspect in the
pharmaceutical development and it constitutes an essential part of
a state-of-the-art development programme. The current knowl-
edge about the age-appropriateness of different dosage forms is
still fragmented or limited. The regulatory perspectives on
acceptability testing were presented by Mr. Piotr Kozarewicz
(EMA). The aim was to provide an update on current thinking and
understanding of the problem, and discussing issues related to the
acceptability testing. The overview just ﬂagged the problem and
was meant as the starting block for further discussion on aspects
relating to acceptability testing of dosage forms in children's
proposition.
The plenary talks were followed by focus sessions centred
around EuPFI workstreams. The ﬁrst focus session on age
appropriateness of formulations included a talk by Mr. Simon
Bryson (on patient centred administration of friendly dosage
form). Mr. Bryson described the studies conducted at Alder Hey
Children’s Hospital, UK, aiming to determine which factors
relating dose form and which organoleptic properties of a
medicinal product inﬂuence the medication adherence in
chronically ill patients aged between 3 and 11 years. The second
focus session on modiﬁcations of dosage forms required for
children (MDFRC) covered a talk on paediatric ad hoc preparation
of Tamiﬂu by Dr. Carsten Timpe (Roche). An overview about
extemporaneous preparations for children along with a case
study of oseltamivir phosphate (Tamiﬂu) was presented. He
explained the challenges in developing age appropriate formu-
lations for children and modiﬁcation of dosage forms required for
children and discussed how these challenging objectives could be
achieved both in Europe and the US against the background of
health authority expectations. The development and submission
experiences on respiratory product for young children were
shared by Dr. Stefan Leiner (Boehringer Ingelheim Pharma GmbH
& Co. KG) as part of devices focus session. The ﬁnal focus session
on taste masking and taste testing included an update on inter
laboratory testing of e-tongues was given by Dr. Mariam Pein
(Heinrich-Heine-University).
As previously, the soapbox sessions provided food for thought
and prompted some good discussion. Range of topics were covered
related to age appropriateness of formulation, taste masking and
taste testing, modiﬁcation of dosage forms required for children,
excipients and administration devices. This year the ‘best poster
award’ was introduced. The overall purpose with the award was to
encourage the students to share experiences and results with
others through quality poster presentations. The award was kindly
sponsored by PCCA (Professional Compounding Centers of
America) and was presented to the winners, Ms. Ramona Trastullo,
Ms. Eva Julia Laukamp for "Immediate release carbamazepine
formulation for individually dosing by the solid dosage pen" and
Ms. Sejal Ranmal. Peer reviewed abstracts can be found at http://
eupﬁ.org/Conference%202013%20/Abstract%20compilation%
20EuPFI%202013_ﬁnal.pdf.
Similarly, the innovative show cases introduced this year
provided companies an opportunity to present less traditional yet
relevant technologies for children medicines. Different topics
covered included:
1. Patient centric medication – elegant dose forms for developing
better treatments: Leon Grother (Catalent) presented the Zydis
solution to help solve complex taste masking, bioavailability,
solubility, and permeability challenges for development ofpatient-tailored medication with excellent dispersion time,
palatability and mouth feel.
2. Taste masking using an aqueous ethylcellulose ﬁlm coating:
Kevin Hughes (Colorcon) presented the surelease taste
masking project evaluating the use of surelease, a barrier
membrane coating formulation with paediatric precedence of
use, on taste masking of acetaminophen (APAP) immediate
release granules.
3. Innovative micropellets for paediatrc drug products and
orodispersible ﬁlms: Annette Grave (Glatt) presented the
Glatt ﬂuid bed Wurster HSTM technology for the development
of taste masked micropellets of hydrocortisone.
4. Combining taste masking and convenient application –
innovative formulation concepts for children: Dr. Sandra Klein
(Losan Pharma GmbH) presented Losan’s toolbox (orodisper-
sible granules, taste masking technologies, single unit dosage
form: stick pack technology, unique formulation concepts:
Liquitab) to address the challenges in formulating better
medicines for children.
5. Orodispersible ﬁlms – a new treatment option especially for
children: Dr. Armin Breitenbach (tesa Labtec) presentation was
focussed on tesa Labtec oral ﬁlm technology.
Two industrial case studies were presented with Dr. Gensine
Winzerburg (Novartis) highlighting the PIP statistics generated since
regulation came into force and presented the challenges and issues
related to PIPs (quality/non-quality/clinical), while Dr. Albertina
Arien (Janssen and Janssen) shared the experience and learnings on
recent PIPs through three case studies: (1) paediatric dosage form for
treatment of tuberculosis; (2) age appropriate formulation for
injectables; and (3) development of combination product.
The “rapid communications” in this IJP special issue résumé the
oral presentations that took place over 2 days:
1. Report on workshop 1: neonat/peads pharmacology.
2. Report on workshop 2: introduction to paediatric regulatory
framework.
3. Paediatric biopharmaceutics: current status and future deci-
sions.
4. Patient involvement in paediatric medicine development and
improving formulations.
5. Patient-centred administration friendly dosage forms – Simon
Bryson, Proveca Ltd., Cheshire, United Kingdom.
6. How do Japanese children take their medicines?
7. The place of dosage form innovation and the OTC market: the
price to pay.
8. A respiratory product for young children – development and
submission experiences.
9. Regulatory perspectives on acceptability testing of dosage
form in children.
10. Review of PIPS.
Moreover, presentation on inter laboratory testing of e-tongues
was selected for full-length manuscript.
In conclusion, this conference brought together a diverse array
of opinion concerning paediatric drug development.
Over the past few years, the responsibility of the scientiﬁc
community to develop and exploit existing, emerging, and novel
technologies to achieve the goal of developing better medicines
for children has increased. There have been advances in paediatric
drug development and attention to regulatory and ethical issues
has progressed so that more paediatric trials are conducted. The
gap is shrinking. Despite this progress, much remains to do. There
are still on-going issues relating to excipients, appropriateness of
the route of administration or pharmaceutical form, dosing
accuracy and patient’s acceptability. A stronger focus on all these
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the treatment duration, could streamline the paediatric formula-
tion development process. A part of the path forward was
discussed and will continue to be discussed at the upcoming 6th
EuPFI conference to be convened in Athens, on 17th and 18th
September 2014 in partnership with APV (International Associa-
tion of Pharmaceutical Technology). There is a real opportunity to
share and learn from the lessons of the past for the future
implementation of the paediatric regulation and for the beneﬁt of
children. More information is available on EuPFI website (http://
www.eupﬁ.org).
This special issue is dedicated to the late Prof. Valls-i-Soler. He
will be remembered for his spirit and dedication for improvinghealth care in neonatal infants (http://www.euroneonet.eu/pag-
inas/publicas/euroneo/euroneonet/Documents/Inmemoriam.pdf).
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